European Society of Cardiology (ESC) Congress 2021

virtual 27 August 2021 - 30 August 2021

CV safety of degarelix vs leuprolide: Results remain inconclusive

06 Oct 2021 by

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

CV safety of degarelix vs leuprolide: Results remain inconclusive

06 Oct 2021

1-month DAPT may be enough post-PCI

06 Oct 2021 by

In patients at high-bleeding risk (HBR) implanted with a drug-eluting coronary stent, 1 month of dual antiplatelet therapy (DAPT) is as good as 3 months or longer – with significantly less bleeding – in the MASTER DAPT* trial, that experts said shorter DAPT post coronary stenting may be the strategy moving forward.

1-month DAPT may be enough post-PCI

06 Oct 2021

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

25 Sep 2021 by

The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

25 Sep 2021

BP target in older Chinese: How low can clinicians go?

22 Sep 2021 by

Under 130 mm Hg – that’s how low clinicians can go in terms of systolic blood pressure (SBP) to reduce cardiovascular events in older, hypertensive Chinese patients, suggests the multicentre STEP* trial.

BP target in older Chinese: How low can clinicians go?

22 Sep 2021

Salt substitute may slash stroke risk

20 Sep 2021 by

Swapping regular salt for a reduced-sodium salt substitute may cut stroke, major adverse cardiovascular event (MACE)*, and death rates in individuals with a risk of stroke, according to results of the SSaSS** trial.

Salt substitute may slash stroke risk

20 Sep 2021

Quadpill trumps monotherapy in BP lowering

18 Sep 2021 by

A quadruple combination containing quarter doses of four blood pressure (BP)-lowering drugs in a single pill — termed a quadpill — led to better BP control than using monotherapy for initial treatment of hypertension, according to the QUARTET study presented at ESC 2021.

Quadpill trumps monotherapy in BP lowering

18 Sep 2021

Flu vaccine cuts all-cause, CV death risk in cardiac patients

17 Sep 2021 by

Receiving an influenza vaccination after hospitalization for an invasive coronary procedure or a myocardial infarction (MI) may reduce the risk of all-cause or cardiovascular (CV) death, according to results of the IAMI* trial.

Flu vaccine cuts all-cause, CV death risk in cardiac patients

17 Sep 2021

Binge drinking in early adulthood linked to increased arterial stiffness

17 Sep 2021 by

Alcohol consumption during late adolescence and early adulthood was associated with increased arterial stiffness, which may lead to future cardiovascular events, according to a study presented at ESC 2021.

Binge drinking in early adulthood linked to increased arterial stiffness

17 Sep 2021

CVD risk increases with intake of saturated fats from meat

16 Sep 2021 by

Regular intake of saturated fatty acids (SFA) from meat could increase cardiovascular disease (CVD) risk whereas dairy sources, grains, fruits, and vegetables could be cardio-protective, suggests a study in the UK.

CVD risk increases with intake of saturated fats from meat

16 Sep 2021

Empagliflozin reduces CV death or HHF in HFpEF

16 Sep 2021 by

Empagliflozin significantly reduces the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) vs placebo in patients with heart failure with preserved ejection fraction (HFpEF) with or without diabetes, according to results of the EMPEROR-Preserved trial presented at the European Society of Cardiology (ESC) Congress 2021.

Empagliflozin reduces CV death or HHF in HFpEF

16 Sep 2021